IRLAB Therapeutics - Ipsen confirms commitment with clinical studies
IRLAB Therapeutics announced that Ipsen, the out-licensing partner for its lead asset, mesdopetam, has commenced standard clinical studies for the drug. These preparatory studies are necessary to progress into Phase III and confirm the arrangement is progressing as planned. The three studies to be conducted on healthy volunteers include a pharmacokinetic, a drug-to-drug interaction and a mass balance study, and will be run in parallel with the ongoing Phase IIb study conducted by IRLAB. As top-line data from Phase IIb are expected around the end of CY22, the data from the Ipsen studies will support the late-stage development of the drug. We maintain our estimates and valuation of IRLAB at SEK6.40bn or SEK123.7 per share.IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.